Breckenridge Signs Agreement with IDL
Will develop and market ANDA for cancer drug. - Sept. 25, 2008

Breckenridge Announces Approval of Generic
Will market Novo Nordisk's generic Activella®. - April 17, 2008

Breckenridge Enters Agreement With Orit Laboratories
Will market two separate generic ANDA products. - April 10, 2008

Breckenridge Enters Agreement With Helm AG
Will develop and manufacture a generic ANDA product. - March 31, 2008

Breckenridge Settles "Paragraph IV" Litigation
FDA Approves Oxcarbazepine; generic version of Trileptal(R). - January 11, 2008

Breckenridge Signs Long Term Agreement with Helm AG (Hamburg, Germany)
Will develop and market generic tablet and ANDA product – December 18, 2007

Breckenridge Develops ANDA With Midland HealthCare, LLC
Will develop and market generic liquid ANDA – july 25, 2007

Breckenridge Enters Agreement with Chemo/Liconsa
Companies to manufacture and market Generic ANDA – june 25, 2007

Breckenridge Signs Letter of Intent
Enters into long-term agreement with Orbus Pharma – May 31, 2007

Breckenridge Moves to Generic Name- EEMT
Abandons “Syntest” trade name – March 13, 2007

FDA Warning Letters Concerning Ergotamine-Containing Products
FDA orders manufacturing to cease, March 6, 2007

Breckenridge Announces New VP
Anthony R. Mihelich, R.Ph named new VP of Corporate Development, Feb. 5, 2007

Syntho Recall Notice
Breckenridge cooperating with Syntho-initiated recall, Oct. 6, 2006

Breckenridge Files ANDA for Oxcarbazepine
Seizure drug to be added to Breckenridge inventory, Sept. 15, 2006

Breckenridge Enters Marketing Agreement
Will market PEG3350, generic version of Miralax®, Sept. 29, 2006

Breckenridge to Market Meloxicam
FDA approval received to market 7.5mg and 15mg tablets, July 19, 2006

FDA Notice Regarding Carbinoxamine
Docket No. 2006N-0229 - Fed Reg. 71, No. 111, June 9, 2006

Florida Pedigree Compliance
Effective July 1, 2006